In conclusion, the G388R mutation of the FGFR4 gene does not appear to be an effective prognostic marker of breast cancer, contrary to the findings of Bange et al. Larger patient cohorts (139 vs 46 node-positive patients) and powerful statistical methods (Breslow, Tarone – Ware or Peto – Prenctice) were used in the present study, but no statistically significant difference in DFS according to G388R status was detected during early follow-up. The gene discussed is FGFR4; the disease is breast carcinoma.